



**Enlitic, Inc.**  
1635 Foxtrail Drive, Suite 111A  
Loveland, CO 80538

1<sup>st</sup> July 2026

## First Australian Ensign Contract Secured with Lumus Imaging

Enlitic, Inc. (ASX: ENL) (“Enlitic” or the “Company”) has signed a three-year Ensign subscription agreement with Lumus Imaging (“Lumus”), a leading Australian diagnostic imaging provider. The agreement is Enlitic’s first Ensign subscription in the Australian market and establishes a deployment within a major national imaging network.

Lumus will deploy the full Ensign platform from the outset across three use cases: Hanging Protocols (which standardises how imaging studies are presented to radiologists at the point of read), de-identification, and AI validation. This multi-use-case adoption reflects growing customer demand for Ensign as a data infrastructure platform, rather than for data migration alone.

The agreement marks Enlitic's entry into the Australian subscription market and demonstrates growing real-world demand for Ensign across core imaging workflows. It provides a reference deployment for further enterprise subscriptions across Australia and the wider Asia Pacific region and supports the Company's transition from migration and services revenue toward a recurring SaaS model.

The agreement carries a contract value of US\$248,000 (~A\$359,000<sup>1</sup>) over its three-year term. Go-live is expected to occur during H2 2026 and the enterprise pricing reflects the workflow, functionality and study-volume scope of each deployment, rather than site count alone.

Lumus operates on Intelrad's IntelePACS, enabling deployment through Enlitic's existing integration with that platform. The integration was first deployed at RHCNZ Medical Imaging Group, New Zealand’s largest private radiology provider (see ASX announcement: 12 May 2026). Intelrad is one of eight global OEMs actively engaged with Enlitic's offering, and this second enterprise deployment demonstrates the repeatability of Enlitic's OEM channel.

Lumus, formerly Healthcare Imaging Services, is an established Australian diagnostic imaging provider with more than 30 years of operating history. It operates 150 locations across Australia supported by more than 2,000 healthcare professionals, delivering a full range of imaging modalities including MRI, CT, ultrasound, mammography, X-ray, PET/CT and nuclear medicine.

**Enlitic CEO Michael Sistenich said:** *“Signing Lumus as our first Australian Ensign subscription customer is an important entry point into the Australian market. Lumus’s decision to adopt the full Ensign platform, across hanging protocols, de-identification and AI validation, shows both real demand for the technology and its breadth across core imaging workflows. This multi-year agreement provides a foundation to grow the relationship over time and directly supports our strategy of building recurring SaaS revenue in the large medical imaging sector.”*

---

<sup>1</sup> US\$248,000 converted based on a USD:AUD exchange rate of 0.6908, being the exchange rate on 30 June 2026.

## ENDS

This announcement was authorised for release by the Board of Enlitic, Inc.

### Enquiries

#### Enlitic Investor Relations

Australia:

[invest\\_au@enlitic.com](mailto:invest_au@enlitic.com)

#### Six Degrees Investor Relations

Henry Jordan

[Henry.jordan@sdir.com.au](mailto:Henry.jordan@sdir.com.au)

+61 431 271 538

### About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, Xray and ultrasound images) and licences such products to healthcare providers. Enlitic's products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at [enlitic.com](http://enlitic.com).

Enlitic's CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.

### Forward-looking statements

Certain statements made during or in connection with this announcement contain or comprise certain forward-looking statements regarding the Company, its projected cash flow, financial performance, its customer contracts and customer pipeline and product development. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such expectations are only predictions and are subject to inherent risks and uncertainties which could cause actual values, results, performance or achievements to differ materially from those expressed, implied or projected in any forward looking statements and no assurance can be given that such expectations will prove to have been correct.

Accordingly, results could differ materially from those set out in the forward-looking statements as a result of, among other factors, changes in economic and market conditions, delays or changes in product development and realisation of customer pipeline, changes in demand, success of business and operating initiatives, changes in the regulatory environment and other government actions, fluctuations in exchange rates and business and operational risk management.

To the maximum extent permitted by law, each of the Company, its officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in these forward-looking statements and excludes all liability whatsoever (including in negligence) for any loss or

For personal use only

damage which may be suffered by any person as a consequence of any information in forward-looking statements or any error or omission. The Company undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events other than required by the applicable laws, including the ASX Listing Rules. Accordingly, you should not place undue reliance on any forward-looking statement.

For personal use only